Latest Breaking News On - Anticancer therapies - Page 1 : comparemela.com

MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors

MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Carlos rojasBradford hillInvestigacion clinicaAnticancer therapies congressAnticancer therapiesCentro de investigacion clinica

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Israel generalComunidad autonoma de catalunaOmar saavedraAnticancer therapies congressHebron institute of oncologyEarly drug development unitAnticancer therapiesHebron instituteSmo targeted anticancer therapies congressSolid tumors

Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

Giuseppe curiglianoUniversity of milanoAnticancer therapies congressAnticancer therapiesMedical oncologyClinical divisionEarly drug developmentEuropean instituteIstituto europeoExact sciencesSmo targeted anticancer therapies congressSolid tumors

LoRusso named the Amy and Joseph Perella Professor of Medicine

Patricia LoRusso is an internationally recognized expert in drug development and early-phase clinical investigation of novel cancer therapies.

United statesPatricia lorussoClinical cancer researchBurchenal award for clinical cancer researchAmerican association for cancer researchClinical trials taskEisenberg centerNational organization of italian american womenNational cancer instituteWorld affairs council of connecticutAmerican society of clinical oncologyMichigan state university distinguished alumni awardHospital cancer center onePrecision combination therapy taskCancer therapy evaluation programGlobal affairs committee

Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates

Phase 1b/2 trial of AsiDNA™ in combination with olaparib in the United States in recurrent ovarian, breast and metastatic castration-resistant prostate cancer continues to enroll. | April 24, 2023

United statesSan antonioFrance generalShefali agarwalInstitut curieJulien miaraGustave roussyJudith grecietOnxeo sa euronextDanielle guyot caparrosMarie dutreix institut curieDrug administrationGilles favre toulouse cancer research centerCompany groupAnticancer therapies congressEuropean union